Login to Your Account

Deals And M&A NEWS

SHANGHAI – Beigene Ltd. nabbed the Asia-Pacific rights to sitravatinib from Mirati Therapeutics Inc. in a $10 million cash deal, valued at $123 million when additional milestones roll in.

Foundation Medicine Inc. has struck up a partnership with Pfizer Inc. to develop and eventually market companion diagnostics (Cdx) for its comprehensive genomic profiling (CGP) assay, Foundationone Cdx. FDA-approved Foundationone Cdx provides genomic profiles and incorporates additional diagnostic information on solid tumors.

SAN FRANCISCO – The 36th Annual J.P. Morgan Healthcare Conference started off with a bang Monday, as Celgene Corp. talked up a proposed $7 billion acquisition of Impact Biomedicines Inc. built around Impact’s lead candidate, fedratinib.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: